Entera Bio (ENTX) is trading down at $2.62 (-8.39%), as of the latest quote. It operates in the Health Care sector.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | $500.0K | $236.0K | $365.0K | $571.0K | $134.0K | $0 | $181.0K | $42.0K |
| Growth (year over year) | — | — | — | −52.8% | +54.7% | +56.4% | −76.5% | −100.0% | — | −76.8% |
| Gross profit | — | — | — | $26.0K | $65.0K | $198.0K | $33.0K | $0 | $9.00K | $0 |
| Gross margin | — | — | — | 11.0% | 17.8% | 34.7% | 24.6% | — | 5.0% | 0.0% |
| Operating income | −$5.37M | −$11.3M | −$10.9M | −$11.5M | −$11.2M | −$12.2M | −$13.0M | −$8.89M | −$9.59M | −$11.5M |
| Operating margin | — | — | −2172.2% | −4853.4% | −3059.7% | −2139.6% | −9714.2% | — | −5295.6% | −27450.0% |
| Net income | −$1.20M | −$11.2M | −$10.3M | −$10.8M | −$11.2M | −$12.2M | −$13.1M | −$8.89M | −$9.54M | −$11.4M |
| Net margin | — | — | −2060.8% | −4574.2% | −3072.9% | −2134.3% | −9754.5% | — | −5271.3% | −27235.7% |
| EPS (diluted) | $0.78 | $2.49 | $1.31 | $0.89 | $0.67 | $0.47 | $0.45 | $0.31 | $0.25 | $0.25 |
| Balance sheet | ||||||||||
| Cash and equivalents | $4.16M | $11.7M | $7.51M | $15.2M | $8.59M | $24.9M | $12.3M | $11.0M | $8.66M | $7.11M |
| Total assets | — | $13.3M | $13.3M | $16.7M | $9.72M | $26.0M | $13.1M | $11.8M | $9.39M | $16.0M |
| Total liabilities | — | $44.8M | $3.23M | $4.78M | $2.21M | $3.42M | $1.37M | $1.38M | $1.31M | $2.89M |
| Shareholders' equity | −$25.2M | −$31.6M | $10.1M | $13.8M | $7.51M | $22.6M | $11.8M | $10.4M | $8.08M | $13.1M |
| Cash flow | ||||||||||
| Operating cash flow | −$3.14M | −$4.53M | −$9.80M | −$8.92M | −$10.6M | −$9.06M | −$12.5M | −$7.31M | −$6.82M | −$7.37M |
| Capital expenditure | $41.0K | $51.0K | $68.0K | $40.0K | $53.0K | $17.0K | $47.0K | $17.0K | $3.00K | $107.0K |
| Free cash flow | −$3.18M | −$4.58M | −$9.86M | −$8.96M | −$10.6M | −$9.08M | −$12.5M | −$7.33M | −$6.82M | −$7.48M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $42.0K | $82.0K | $42.0K | $0 | $0 | — | $0 | $0 |
| Growth (year over year) | — | — | — | −100.0% | −100.0% | — | −100.0% | — |
| Gross profit | $0 | $0 | $0 | $0 | $0 | — | $0 | $0 |
| Gross margin | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Operating income | −$3.02M | −$2.34M | −$2.56M | −$2.67M | −$3.26M | — | −$3.54M | −$4.56M |
| Operating margin | −7192.9% | −2850.0% | −6102.4% | — | — | — | — | — |
| Net income | −$3.02M | −$2.36M | −$2.57M | −$2.66M | −$3.20M | — | −$3.50M | −$7.31M |
| Net margin | −7192.9% | −2875.6% | −6111.9% | — | — | — | — | — |
| EPS (diluted) | $0.08 | $0.06 | $0.06 | $0.06 | $0.07 | — | $0.07 | $0.14 |
| Balance sheet | ||||||||
| Cash and equivalents | $6.92M | $8.66M | $12.6M | $10.9M | $8.57M | $7.11M | $4.14M | $11.3M |
| Total assets | $7.74M | $9.39M | $21.6M | $19.7M | $17.4M | $16.0M | $13.1M | $19.5M |
| Total liabilities | $1.29M | $1.31M | $2.22M | $2.41M | $2.17M | $2.89M | $2.44M | $12.2M |
| Shareholders' equity | $6.45M | $8.08M | $19.4M | $17.3M | $15.2M | $13.1M | $10.7M | $7.27M |
| Cash flow | ||||||||
| Operating cash flow | −$2.15M | −$1.47M | −$1.40M | −$1.63M | −$2.50M | — | −$3.09M | −$3.46M |
| Capital expenditure | $0 | $3.00K | $8.00K | $29.0K | $43.0K | — | $0 | $3.00K |
| Free cash flow | −$2.15M | −$1.47M | −$1.41M | −$1.66M | −$2.54M | — | −$3.09M | −$3.47M |
From Entera Bio's 10-K, 10-Q, 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Entera Bio in our feed yet.